Dr. Shikha Jain
Claim this profileUniversity of Illinois
Studies Colorectal Cancer
Studies Lung Cancer
16 reported clinical trials
35 drugs studied
Area of expertise
1Colorectal Cancer
Stage IV
Stage III
dMMR positive
2Lung Cancer
Stage IV
BRCA1 positive
BRCA2 positive
Affiliated Hospitals
Clinical Trials Shikha Jain is currently running
Chemotherapy + Radiotherapy
for Esophageal and Gastric Cancer
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.
Recruiting2 awards Phase 320 criteria
Pre- and Post-Surgery Chemotherapy
for Gallbladder Cancer
This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before surgery may make the tumor smaller; therefore, may reduce the extent of surgery. Additionally, it may make it easier for the surgeon to distinguish between normal and cancerous tissue. Giving chemotherapy after surgery may kill any remaining tumor cells. This study will determine whether giving chemotherapy before surgery increases the length of time before the cancer may return and whether it will increase a patient's life span compared to the usual approach.
Recruiting1 award Phase 2 & 315 criteria
More about Shikha Jain
Clinical Trial Related5 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Shikha Jain has experience with
- Bevacizumab
- Fluorouracil
- Nivolumab
- Atezolizumab
- Leucovorin
- Oxaliplatin
Breakdown of trials Shikha Jain has run
Colorectal Cancer
Lung Cancer
Cancer
Colon Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Shikha Jain specialize in?
Shikha Jain focuses on Colorectal Cancer and Lung Cancer. In particular, much of their work with Colorectal Cancer has involved Stage IV patients, or patients who are Stage III.
Is Shikha Jain currently recruiting for clinical trials?
Yes, Shikha Jain is currently recruiting for 8 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Shikha Jain has studied deeply?
Yes, Shikha Jain has studied treatments such as Bevacizumab, Fluorouracil, Nivolumab.
What is the best way to schedule an appointment with Shikha Jain?
Apply for one of the trials that Shikha Jain is conducting.
What is the office address of Shikha Jain?
The office of Shikha Jain is located at: University of Illinois, Chicago, Illinois 60612 United States. This is the address for their practice at the University of Illinois.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.